The Recombinant Human VEGF-A/VEGF121 Protein is a biologically active recombinant protein that plays a significant role in various cellular processes and signaling pathways in human biology. This protein is widely employed in immunological research, cell biology studies, protein-protein interaction analyses, and therapeutic development, providing researchers with a reliable tool for investigating VEGF-A/VEGF121 function and its implications in health and disease.
This product (SKU: RPCB0791) is produced using HEK293 cells and features a N-His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 14.91 kDa with an observed molecular weight of 17-22 kDa under denaturing conditions, achieving ≥ 95 % as determined by SDS-PAGE.. Functional bioactivity has been validated through rigorous quality control assays, confirming its suitability for demanding research applications.
Key Features
High Purity by Affinity Chromatography
Mammalian & Bacterial Expression Systems
High lot-to-lot consistency via strict QC
Product Name:
Recombinant Human VEGF-A/VEGF121 Protein
SKU:
RPCB0791
Size:
10 μg , 20 μg , 50 μg , 100 μg
Reactivity:
Human
Synonyms:
VEGFA, MVCD1, VEGF, VPF, vascular endothelial growth factor A, MVCD1, VEGF, VPF, L VEGFA, VEGF A
High quality, high purity and low endotoxin recombinant Recombinant Human VEGF-A/VEGF121 Protein (RPCB0791), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 0.1 EU/μg of the protein by LAL method.
Purity:
≥ 95 % as determined by SDS-PAGE.
Formulation:
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation.
Bio-Activity:
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF121 at 1 μg/mL (100 μL/well) can bind Recombinant Human VEGFR2 with a linear range of 4-10 ng/mL.
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. The ED 50 for this effect is 0.09-0.36 ng/mL.
Recombinant Human VEGFA(40 ng/mL) and bFGF(50 ng/mL, RPCB0791) induce mesoderm cells to differentiate into hematopoietic stem and progenitor cells. After 4 days induction, pebbly-like CD43+ hematopoietic stem and progenitor cells appeared in the hematogenic endothelium.
Reconstitution:
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
This protein is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This protein is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome.
Recombinant Human VEGF-A/VEGF121 Protein was determined by SDS-PAGE under reducing (R) and non-reducing (NR) conditions.
Immobilized Recombinant Human VEGF121 at 1 μg/mL (100 μL/well) can bind Recombinant Human VEGFR2 with a linear range of 4-10 ng/mL.
